Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Verve Therapeutics Inc (VERV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/25/2025: VERV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $13.12
1 Year Target Price $13.12
| 6 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57.49% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/25/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 994.04M USD | Price to earnings Ratio - | 1Y Target Price 13.12 |
Price to earnings Ratio - | 1Y Target Price 13.12 | ||
Volume (30-day avg) 10 | Beta 2.24 | 52 Weeks Range 2.86 - 11.40 | Updated Date 08/14/2025 |
52 Weeks Range 2.86 - 11.40 | Updated Date 08/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.11 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.6858 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -111.1% |
Management Effectiveness
Return on Assets (TTM) -19.35% | Return on Equity (TTM) -34.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 565603941 | Price to Sales(TTM) 16.68 |
Enterprise Value 565603941 | Price to Sales(TTM) 16.68 | ||
Enterprise Value to Revenue 9.49 | Enterprise Value to EBITDA -0.4 | Shares Outstanding 89312200 | Shares Floating 65365170 |
Shares Outstanding 89312200 | Shares Floating 65365170 | ||
Percent Insiders 5.1 | Percent Institutions 94.69 |
Upturn AI SWOT
Verve Therapeutics Inc
Company Overview
History and Background
Verve Therapeutics Inc. was founded in 2018 with the goal of revolutionizing the treatment of cardiovascular disease through gene editing. It has since made significant progress in developing gene editing therapies for inherited lipid disorders.
Core Business Areas
- Cardiovascular Gene Editing: Verve is focused on developing single-course gene editing medicines for cardiovascular disease, primarily targeting the liver to reduce disease-causing blood lipids, such as cholesterol.
Leadership and Structure
The company is led by Sekar Kathiresan, M.D., as CEO. The organizational structure includes research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- VERVE-101: VERVE-101 is Verve's lead product candidate, designed to inactivate the PCSK9 gene in the liver to durably reduce LDL-C levels. It is in clinical development. Competitors include existing LDL-C lowering therapies like statins (generics, broad market share), PCSK9 inhibitors (Amgen, Regeneron), and bempedoic acid (Esperion).
- VERVE-201: VERVE-201 is a gene editing therapy designed to target ANGPTL3 for treating homozygous familial hypercholesterolemia (HoFH). Competitors include similar medications that treat elevated blood lipids.
Market Dynamics
Industry Overview
The gene editing market for cardiovascular disease is emerging, with significant potential for therapies that can provide durable LDL-C reduction. High unmet need for patients who cannot reach LDL-C goals with existing therapies.
Positioning
Verve is a pioneer in in vivo cardiovascular gene editing. Its competitive advantage lies in its proprietary gene editing technology and its focus on single-course therapies.
Total Addressable Market (TAM)
The TAM for cardiovascular disease therapies is very large, estimated to be hundreds of billions of dollars. Verve is aiming to capture a significant share by targeting patients with high unmet need.
Upturn SWOT Analysis
Strengths
- Pioneering gene editing technology
- Strong intellectual property portfolio
- Experienced leadership team
- Focus on single-course therapies
Weaknesses
- Early stage clinical development
- High development costs and uncertainty
- Reliance on successful clinical trial outcomes
- Potential regulatory hurdles
Opportunities
- Expansion into other cardiovascular diseases
- Partnerships with pharmaceutical companies
- Regulatory approval and commercialization of lead products
- Improved gene editing technology and delivery methods
Threats
- Competition from other gene editing companies
- Adverse clinical trial results
- Regulatory setbacks
- Ethical concerns surrounding gene editing
Competitors and Market Share
Key Competitors
- AMGN
- REGN
- ESPR
Competitive Landscape
Verve competes with established pharmaceutical companies in the cardiovascular space, as well as other gene editing companies. Verve's advantage is its focus on single-course therapies, but it faces challenges related to clinical trial success and regulatory approval.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by pipeline development and clinical trial progress.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approval of Verve's lead product candidates.
Recent Initiatives: Recent initiatives include advancing VERVE-101 and VERVE-201 through clinical trials, expanding research programs, and exploring strategic partnerships.
Summary
Verve Therapeutics is a pioneering company in the field of cardiovascular gene editing with a promising, innovative approach using single-course treatments. The company's success hinges heavily on the outcomes of its clinical trials, and potential regulatory hurdles pose significant risks. It currently competes with well-established pharmaceutical companies, but its unique technology and strategy could lead to substantial gains if successful. Investors should be aware of the high-risk, high-reward nature of this biotech investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Verve Therapeutics Inc. company website, SEC filings, Analyst reports, Market research reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual risk tolerance and thorough research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Verve Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-06-17 | Co-Founder, CEO & Director Dr. Sekar Kathiresan M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 274 | Website https://www.vervetx.com |
Full time employees 274 | Website https://www.vervetx.com | ||
Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The company's product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hypercholesterolemia (HeFH); VERVE-102 that is being evaluated in the Heart-2 trial, an open-label Phase 1b clinical trial in adult patients with HeFH, and/or premature coronary artery diseases; VERVE-201, which targets ANGPTL3 and permanently turn off the ANGPTL3 gene in the liver; and VERVE-301, a development candidate that uses a novel in vivo gene editing approach to permanently turn off the LPA gene in the liver to reduce blood Lp(a) levels. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; a license agreement to lipid technology with Novartis Pharma AG; Eli Lilly and Company; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is based in Boston, Massachusetts. As of July 25, 2025, Verve Therapeutics, Inc. operates as a subsidiary of Ridgeway Acquisition Corporation.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.